On Feb. 15, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval of Tepmetko (tepotinib) for people living with metastatic non-small cell lung cancer (NSCLC) with a MET-Exon 14 mutation. Tepmetko (tepotinib) initially received accelerated approval in [...]
Many people being treated for lung cancer will eventually develop resistance to their current therapies, causing them to stop working. When this happens, and a person’s cancer starts to progress on their current treatment, their healthcare team will take [...]
Question: My insurance does not cover the cost of my lung cancer treatment. What are my options? Answer: When insurance does not cover the cost of lung cancer drug treatments, there are a few options to explore for financial [...]
Answered by Michele Szafranksi, MS, RD, CSO, LDN, Clinical Nutrition Manager, Section of Oncology Nutrition, Department of Supportive Oncology, Levine Cancer Institute Question: I was diagnosed with lung cancer a few weeks ago and am about to start treatment. [...]
Contributing Authors: GO2 for Lung Cancer Associate Director, Clinical Research, Andrew Ciupek, PhD and Manager, Precision Medicine & Navigation, Matthew Reiss, MSE, PhD Each year, researchers, physicians, and industry partners gather at the European Society for Medical Oncology [...]
On Nov. 16, 2023, the U.S. Food and Drug Administration (FDA) approved Augtyro (repotrectinib) for people living with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a ROS1 gene mutation. The approval was based on results from [...]
Question: I’ve just been diagnosed with lung cancer, and my doctor said I may need to have surgery. What can I expect? Answer: Your healthcare team will explain the best type of surgery for you, but the goal will [...]
Author: GO2 for Lung Cancer Specialist, Science & Research, Brittney Nichols MPH, BSN-RN Each year, scientists and doctors from across the globe gather at IASLC’s World Conference on Lung Cancer (WCLC) to discuss the latest and greatest in lung [...]
Author: GO2 for Lung Cancer Associate Director, Clinical Research, Andrew Ciupek, PhD With an increasing number of targeted therapies becoming available, making treatment decisions based on the results of biomarker testing has become an essential part of cancer care [...]
Author: GO2 for Lung Cancer's Specialist, Science & Research, Brittney Nichols MPH, BSN-RN The IASLC annual World Conference on Lung Cancer (WCLC) unites lung cancer professionals from across the world to connect and share insights. This goes beyond the [...]